...13.1% as reported. a. b. 15.3% in constant currency. 2. Global vascular revenue grew 22.7%. 3. Global neuro revenue increased 1.5% vs. 2Q21. 4. Co. expanded GM 180 BP sequentially to 64.3%. 5. Non-GAAP operating income $1.6m or 0.8% of revenue. 6. Co. expects to increase revenue in 2H22 and accelerate growth in 2023., with four significant catalysts, three major product launches and presentation of significant clinical data. 7. Expects to continue to expand GM with 70% plus as goal within few years, and Co. plans to increase operating profitability through discipline and operational improvements, not withstanding prevailing downturn in macro economy. These catalysts which include both neuro and vascular, as well as work on GM and operating profitability, will make next 12-18 months, one of the most robust eras ever for PEN. a. 8. Co. is proud of how its team executed, notwithstanding a very difficult operating environment, primarily in US. US growth of 10.2% YoverY was lower than anticipated...
